705250-75-5

Basic information

• Product Name: (E)-Methyl 3-(3,5-Difluorophenyl)Acrylate
• Synonyms: (E)-Methyl 3-(3,5-Difluorophenyl)Acrylate
• CAS NO: 705250-75-5
• Molecular Formula: C₁₀H₈F₂O₂
• Molecular Weight: 198.1661264
• Mol File: 705250-75-5.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (E)-Methyl 3-(3,5-Difluorophenyl)Acrylate(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-Methyl 3-(3,5-Difluorophenyl)Acrylate(705250-75-5)
• EPA Substance Registry System: (E)-Methyl 3-(3,5-Difluorophenyl)Acrylate(705250-75-5)

Safety Data

• Hazardous Substances Data: 705250-75-5(Hazardous Substances Data)

Usage

Description

(E)-Methyl 3-(3,5-Difluorophenyl)Acrylate is a chemical compound characterized by its molecular formula C11H8F2O2. It is an acrylate ester featuring a methyl group and a difluorophenyl group attached to the acrylate moiety. This colorless to pale yellow liquid with a fruity odor is insoluble in water but soluble in most organic solvents. Due to its flammability, it requires careful handling in well-ventilated areas with proper safety measures.

Uses

Used in Organic Synthesis:
(E)-Methyl 3-(3,5-Difluorophenyl)Acrylate is utilized as a key building block in organic synthesis for the creation of various chemicals. Its unique structure allows for the development of a wide range of compounds with diverse applications.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (E)-Methyl 3-(3,5-Difluorophenyl)Acrylate serves as an essential component in the production of different pharmaceuticals. Its incorporation into drug molecules can potentially enhance their efficacy and target specific biological pathways.
Used in Chemical Production:
(E)-Methyl 3-(3,5-Difluorophenyl)Acrylate is also employed in the chemical production industry, where it contributes to the synthesis of a variety of chemical products. Its versatility and reactivity make it a valuable asset in this field.

Upstream product

• 292638-85-8 acrylic acid methyl ester 
• 156545-07-2 3,5-difluorophenylboronic acid 
• 67-56-1 methanol 
• 84315-23-1 (trans)-3-(3,5-difluorophenyl)acrylic acid 
• 74-88-4 methyl iodide 
• 1067-74-9 Methyl diethylphosphonoacetate 
• 32085-88-4 3,5-difluorobenzaldehyde 
• 1099-45-2 ethyl (triphenylphosphoranylidene)acetate 

Downstream Products

• 1604786-89-1 4-(3,5-difluorophenyl)pyrrolidin-2-one 

Relevant articles and documents

Mizoroki-Heck Reaction of Unstrained Aryl Ketones via Ligand-Promoted C-C Bond Olefination

Mizoroki-Heck reaction of unstrained aryl ketone with acrylate/styrene is accomplished via palladium-catalyzed ligand-promoted C-C bond cleavage. Various (hetero)aryl ketones are compatible in the reaction, affording the alkene product in good to excellent yields. Further applications in the late-stage olefination of some drugs, natural products, and fragrance-derived aryl ketones demonstrate the synthetic utility of this protocol. By employing ketone as both the directing group and the leaving group, 1,2-bifunctionalization is achieved via sequential ortho-C-H alkylation/ipso-Heck olefination.

1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS

The invention is directed to substituted pyrrolidinone and imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I: (I) wherein R1, R2, R3, R4, R5, R6, R7, X and Y are as defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases/injuries associated with activated unfolded protein response pathways, such as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson's disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt- Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Phenylaminopropanol derivatives and methods of their use

The present invention is directed to phenylaminopropanol derivatives of formulae I, II, and III: [image] or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, schizophrenia, and combinations thereof.